Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road Database
Industry

China's medical reform fasttracks innovation: U.S. pharma giant

April 01, 2025


Abstract : China's reform efforts to promote research and development on medical innovation and shorten the review and approval time for the launch of related drugs have provided innovation-driven pharmaceutical firms with greater opportunities, a senior executive with U.S. medicine giant Eli Lilly and Company said.

BEIJING, March 31 (Xinhua) -- China's reform efforts to promote research and development on medical innovation and shorten the review and approval time for the launch of related drugs have provided innovation-driven pharmaceutical firms with greater opportunities, a senior executive with U.S. medicine giant Eli Lilly and Company said.

"Related reforms have stimulated innovation in the pharmaceutical sector, accelerating the pace at which new and effective drugs enter the Chinese market and prompting China to become a significant source of global pharmaceutical innovation," Wang Li, Lilly's senior vice president and head of Lilly China Drug Development and Medical Affairs Center, told Xinhua.

The reforms enabled Lilly's Kisunla (donanemab), an innovative treatment seeking to slow the progression in the early stages of Alzheimer's disease (AD), to secure Chinese regulator's approval in December 2024 -- just five months after its first global market approval. The treatment was launched in the Chinese market on Saturday.

"This underscores the regulatory authorities' support for the expedited review and approval of breakthrough therapeutic drugs, marking a significant step forward in delivering innovative treatment options for AD patients," Wang said.

Wang credited China's establishment of four expedited approval channels to facilitate the development and launch of certain drugs. These reforms helped propel a total of 48 Class 1 innovative drug approvals in 2024, up 20 percent year on year, and most of their approval were fast-tracked, according to a report from China's National Medical Products Administration.

"China, as a leading global healthcare market, also serves as a hub for emerging biotechnology research and development, creating an ideal environment for scientific breakthroughs," Wang added.

Earlier this month, Lilly opened its innovation accelerator Lilly Gateway Laboratory in Beijing, the company's fourth facility of its kind and the first to open outside the United States. The Beijing lab is also Lilly's first innovation platform to provide data analytics facilities, offering robust support for businesses focused on advanced technologies and machine learning, according to Wang.

Scan the QR code and push it to your mobile phone

Keyword: innovation pharmaceutical sector medical innovation

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial